EGFR and non-small cell lung carcinoma: Both our studies [8,9] and those of others [10] have shown that the active metabolite of vitamin D3, 1,25(OH)2D3 (1,25-dihydroxyvitamin D3), mitigates EGFR-TKI resistance in NSCLC.